• Best Practices New Normal
  • Digital Dentistry
  • Data Security
  • Implants
  • Catapult Education
  • COVID-19
  • Digital Imaging
  • Laser Dentistry
  • Restorative Dentistry
  • Cosmetic Dentistry
  • Periodontics
  • Oral Care
  • Evaluating Dental Materials
  • Cement and Adhesives
  • Equipment & Supplies
  • Ergonomics
  • Products
  • Dentures
  • Infection Control
  • Orthodontics
  • Technology
  • Techniques
  • Materials
  • Emerging Research
  • Pediatric Dentistry
  • Endodontics
  • Oral-Systemic Health

RevBio Receives FDA Approval for Clinical Trial on Tetranite Implant Stabilizing Biomaterial

News
Article

This biomaterial will undergo testing to see if it will be suitable for use in immediate loading implant situations for patients.

RevBio Receives FDA Approval for Clinical Trial on Tetranite Implant Stabilizing Biomaterial. Image: © RevBio, Inc.

RevBio Receives FDA Approval for Clinical Trial on Tetranite Implant Stabilizing Biomaterial. Image: © RevBio, Inc.

RevBio has received approval from the United States Food and Drug Administration (FDA) to begin clinical trials of its bone adhesive biomaterial Tetranite®. Tetranite, which is described as “osteopromotive” in a press release from RevBio, will be tested by industry veterans Kanyon Keeney, DDS, and Paul Fugazzotto, DDS for the FDA. “The adhesive properties and handling characteristics of this material are incomparable to any product on the market,” Dr Fugazzotto says in the press release.

With Tetranite, RevBio aims to stabilize implant sites and reduce the time it takes for effective dental implant procedures. It uses a pH modified porous formulation to stabilize unstable implants and hopefully enable immediate implant placement. This clinical trial, comprised of 20 patients, will put Tetranite to the test.

“We are truly excited to conduct the study with both Dr Fugazzotto, who will initiate this study enrolling the first cases, along with Dr Keeney,” Alan Pollack, RevBio’s Senior Director of Clinical Operations says in the press release. “The improvements we have made to the technology have accelerated both the bone substitution profile and the product’s adhesive strength. Having also just recently received IRB approval, we look forward to our first patients in the coming weeks.”

RevBio’s Tetranite is an injectable bone adhesive that has been developed for use in a variety of medical applications, including dental, orthopedic, and animal health. Early testing has shown “significant bone in-growth” per the press release.

Related Videos
CDA 2024 Video Interview with Kuraray Noritake's Dinesh Weerasinghe and Richard Young, DDS
Addressing Unmet Needs in Early Childhood Oral Care - an interview with Ashlet Lerman, DDS
CDS 2024: Ivoclar's e.max ZirCAD Prime Blocks with Shashi Singhal, BDS, MS
2024 Chicago Dental Society Midwinter Meeting – Interview with Dinesh Sinha, Senior Technical and Marketing Manager at Kuraray Noritake
Contemporary Cosmetic Dentistry – Part III: Modern Restorative Materials
Contemporary Cosmetic Dentistry – Part II: Arresting Marginal Caries
Contemporary Cosmetic Dentistry – Part I: Closing Black Triangles
Greater New York Dental Meeting interview with Robert Rosenfeld, DDS from Tokuyama Dental America
Related Content
© 2024 MJH Life Sciences

All rights reserved.